Light flashes, patterns, or color changes can provoke seizures in up to 1 in 4000 persons.
Prevalence may be higher because of selection bias. The Epilepsy Foundation reviewed …

The Eigth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT VII, took place in
Sitges, Barcelona from the 10th to 14th September, 2006. Basic scientists, clinical …

Brivaracetam is a novel synaptic vesicle protein 2A (SV2A) ligand reported to be 10 fold
more potent than levetiracetam in animal models of epilepsy. This study reports the binding …

Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since
then, a large variety of new AEDs have been developed and introduced, several of them …

The EEG is an invaluable tool in the diagnosis of epilepsy which guides clinical
management. It helps to determine if attacks are of epileptic origin, allows the estimation of …

Background Adjunctive newer antiseizure medications (ASMs) are being used in patients
with treatment-resistant focal-onset seizures (FOS). An updated network meta-analysis …

Purpose: To evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV), a novel
high‐affinity synaptic vesicle protein 2A ligand that also displays inhibitory activity at …

Objective: To explore efficacy and safety/tolerability of adjunctive brivaracetam (BRV), a
novel, high-affinity synaptic vesicle protein 2A ligand, which also inhibits neuronal voltage …

The field of epilepsy has undergone substantial advances as we develop novel drugs and
devices. Yet considerable challenges remain in develo** broadly effective, well‐tolerated …

Brivaracetam (BRV; Briviact) is a new antiepileptic drug (AED) approved for adjunctive
treatment of focal (partial-onset) seizures in adults. BRV is a selective, high-affinity ligand for …